Carregant...
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asth...
Guardat en:
| Publicat a: | Allergy Asthma Clin Immunol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5216532/ https://ncbi.nlm.nih.gov/pubmed/28070196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-016-0174-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|